title: Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer.
abstract: BACKGROUND
  Phospholipase A2 Group IV C (PLA2G4C) catalyzes the release of certain fatty acids from phospholipids and plays a role in a range of physiological functions, such as remodeling of cell membranes and the production of prostaglandins. Furthermore, it has been proposed that PLA2G4C plays an important role in breast cancer cell chemotaxis. This study aimed to investigate the effect of a single nucleotide polymorphism (SNP) rs1549637 (T>A) of the PLA2G4C gene on the prognosis of colorectal cancer (CRC).
  
  
  METHODS
  Whole blood DNA was extracted from 381 patients with CRC and 618 controls, and a TaqMan SNP genotyping assay was used to determine the distribution of the genotypes. Cancer-specific and disease-free survival was analyzed by Kaplan-Meier graphs and by uni- and multivariable Cox regression.
  
  
  RESULTS
  The cancer-specific survival differed between the genotypes (p = 0.019) and the carriers of the A allele were associated with the highest risk of CRC death, with a hazard ratio (HR) of 1.72 [95% confidence interval (CI) 1.17-2.53, p = 0.006] compared with homozygous carriers of the T allele. This increased mortality in the carriers with the allele A was especially marked in stage II with an HR of 3.84 (95% CI 1.51-9.78, p = 0.005).
  
  
  CONCLUSIONS
  The A allele in PLA2G4C SNP (rs1549637) is associated with a worse prognosis in patients with CRC, especially in stage II disease, and it could be a potential prognostic biomarker in the planning of individual adjuvant therapy in stage II patients.
authors.affiliation: a Laboratory Services , Ryhov County Hospital , Jönköping , Sweden .|b Division of Drug Research, Department of Medical and Health Sciences , Linköping University , Linköping , Sweden .
authors.forename: Renate S
authors.initials: RS
authors.lastname: Olsen
authors.affiliation: c Department of Surgery , Ryhov County Hospital , Jönköping , Sweden .
authors.forename: Roland E
authors.initials: RE
authors.lastname: Andersson
authors.affiliation: c Department of Surgery , Ryhov County Hospital , Jönköping , Sweden .
authors.forename: Niklas
authors.initials: N
authors.lastname: Zar
authors.affiliation: d Department of Clinical Microbiology , Ryhov County Hospital , Jönköping , Sweden , and.
authors.forename: Sture
authors.initials: S
authors.lastname: Löfgren
authors.affiliation: b Division of Drug Research, Department of Medical and Health Sciences , Linköping University , Linköping , Sweden .
authors.forename: Dick
authors.initials: D
authors.lastname: Wågsäter
authors.affiliation: a Laboratory Services , Ryhov County Hospital , Jönköping , Sweden .
authors.forename: Andreas
authors.initials: A
authors.lastname: Matussek
authors.affiliation: e Natural Science and Biomedicine, University College of Health Sciences , Jönköping , Sweden.
authors.forename: Jan
authors.initials: J
authors.lastname: Dimberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality*; D018572:Disease-Free Survival; D005260:Female; D005787:Gene Frequency; D054513:Group IV Phospholipases A2 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies
chemical_list: C472331:PLA2G4C protein, human; D054513:Group IV Phospholipases A2